Bernhardt G. Zeiher - 20 May 2026 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: Director
Issuer ticker: TRDA
Reported as of: 20 May 2026
Net transaction value: +$29,316
SEC form: 4
Accepted by SEC: 21 May 2026, 16:31:31 UTC
Prior SEC filing: 27 Jan 2026
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Key filing fact

Bernhardt G. Zeiher filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 21 May 2026.

Key facts

This page summarizes Bernhardt G. Zeiher's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 16:31.

Change

Previous filing in this sequence was filed on 27 Jan 2026.
Current net transaction value: +$29,316.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971421 Primary reporting owner

Zeiher Bernhardt G

Relationship: Director
Address: C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Purchase

Transaction value: $29,316
Shares: +5,000
Change %
Price: $5.86
Shares after: 5,000
Date: 20 May 2026
Ownership: By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.